Clinical trial
A Study of Monthly Risedronate for Osteoporosis
NCT00247273 · Warner Chilcott, Industry · Completed
Key facts
| NCT number | NCT00247273 |
|---|---|
| Title | A Study of Monthly Risedronate for Osteoporosis |
| Official title | A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO) |
| Lead sponsor | Warner Chilcott, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | risedronate |
| Enrollment | 1,294 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Nov 1, 2005 |
| Last update posted | Apr 22, 2013 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Estonia, Finland, France, Hungary, Lebanon, Norway, Poland and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: